[Drug-drug interactions with Mexidol in patients with ischemic stroke: Analysis of data from randomized clinical trials].

OBJECTIVE

Identification of drug-drug interaction of Mexidol when used in patients with ischemic stroke.

MATERIAL AND

METHODS

The data from randomized controlled clinical trials (RCTs) of the efficacy and safety of Mexidol, EPICA and MIR, in patients with ischemic stroke were analyzed.

RESULTS

The analysis included data from 304 participants of RCT MIR and 150 participants of RCT EPICA. In both studies, antihypertensive drugs were most often used as concomitant therapy (94.1% of participants in the MIR RCT and 98.0% of EPIC RCT). In patients receiving Mexidol, antihypertensive drugs with INN were more often prescribed: enalapril (24.0%), bisoprolol (16.7%), amlodipine (11.8%), lisinopril (8.4%), indapamide (7.9%). In addition to antihypertensive drugs, almost all participants in RCTS MIR and EPIC received antiplatelet drugs (90.1% and 94.0% respectively), lipid-lowering drugs (78.0% and 78.7% respectively) and electrolyte solutions (77.3% and 75.3% respectively). Anticoagulants were prescribed in 24.0% of participants in the MIR RCT and in 34.0% of participants in the EPIC RCT. Analysis of drug interaction models, taking into account the total number of adverse events and the systemic organ class to which they belong, did not reveal a statistically significant change in the frequency of adverse events in patients receiving concomitant therapy along with Mexidol (p>0.05 in all comparison pairs).

CONCLUSION

The analysis did not reveal drug interactions when using Mexidol and all types of concomitant therapy in patients with ischemic stroke. This study confirmed the high safety and good tolerability when using Mexidol in patients receiving multiple medications at the same time.